Premium Nahrungsergänzungsmittel | artgerecht

Immune Cell Transfer Therapy – Overview & Applications

Immune cell transfer therapy is an advanced immunotherapy in which immune cells are transferred to a patient to specifically target diseases such as cancer.

Regular tips about health Regular tips about health

Things worth knowing about "Immune Cell Transfer Therapy"

Immune cell transfer therapy is an advanced immunotherapy in which immune cells are transferred to a patient to specifically target diseases such as cancer.

What is Immune Cell Transfer Therapy?

Immune cell transfer therapy, also known as adoptive cell therapy (ACT), is an innovative treatment approach within immuno-oncology and personalized medicine. In this procedure, immune cells are collected from the patient (autologous) or a healthy donor (allogeneic), expanded or genetically engineered in the laboratory, and then infused back into the body. The goal is to strengthen or reprogram the immune system so that it can more effectively recognize and destroy diseased cells, particularly cancer cells.

Types of Immune Cell Transfer Therapy

Several forms of this therapy exist, each tailored to the specific disease and patient profile:

CAR-T Cell Therapy: The patient's own T cells are genetically modified to carry chimeric antigen receptors (CARs), enabling them to specifically target tumor cells.
TIL Therapy (Tumor-Infiltrating Lymphocytes): Immune cells extracted from the patient's own tumor tissue are expanded in the lab and reinfused to fight the tumor.
NK Cell Transfer: Natural killer (NK) cells are isolated, activated, and transferred to destroy tumor cells or infected cells.
TCR Therapy (T Cell Receptor Therapy): T cells are equipped with specific T cell receptors designed to recognize particular tumor antigens.
Allogeneic Stem Cell Transfer: Immune cells from a healthy donor are transferred, often as part of a hematopoietic stem cell transplantation.

Indications and Applications

Immune cell transfer therapy is used or actively investigated in the following conditions:

Hematological cancers (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma)
Solid tumors (e.g., melanoma, lung cancer, cervical cancer – largely still in clinical trials)
Chronic viral infections (e.g., HIV, cytomegalovirus infections following transplantation)
Autoimmune diseases (in early-stage research)

Mechanism of Action

The central principle of this therapy is the targeted activation and redirection of immune cells. T cells, NK cells, or other immune cells are prepared to recognize tumor-specific or infection-specific antigens. Once infused into the patient, these cells proliferate and selectively attack the target cells. In CAR-T cell therapy, for example, the chimeric antigen receptor binds directly to a surface protein on the tumor cell (e.g., CD19 in B-cell lymphomas), triggering the destruction of that cell.

Treatment Process

The typical treatment process involves the following steps:

Leukapheresis: Immune cells are collected from the patient's blood using a specialized filtration procedure.
Laboratory Processing: The collected cells are expanded, activated, or genetically modified over a period of several weeks.
Conditioning Therapy: Prior to reinfusion, the patient typically receives lymphodepleting chemotherapy to create space for the new immune cells.
Infusion: The engineered cells are returned to the patient via intravenous infusion.
Follow-up Care: Close monitoring for potential side effects is conducted at a specialized medical center.

Side Effects and Risks

This therapy can be associated with serious side effects, including:

Cytokine Release Syndrome (CRS): An excessive immune response characterized by fever, low blood pressure, and potential organ damage, requiring immediate medical management.
Neurological Toxicity (ICANS): Confusion, speech difficulties, or in rare cases cerebral edema.
Infections: The immune suppression during conditioning increases the risk of serious infections.
Graft-versus-Host Disease (GvHD): In allogeneic transfers, donor cells may attack the patient's own tissues.
B-Cell Aplasia: CD19-targeted CAR-T therapies may result in a persistent deficiency of B cells.

Availability and Current Approvals

Several CAR-T cell products have received approval in Europe through the European Medicines Agency (EMA), including tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), and idecabtagene vicleucel (Abecma). These therapies are currently reserved for specialized centers and selected patient populations. Numerous additional approaches are being evaluated in clinical trials (Phases I through III).

References

June CH, Sadelain M. Chimeric Antigen Receptor Therapy. New England Journal of Medicine, 2018; 379(1):64–73.
European Medicines Agency (EMA): Approval information on CAR-T cell therapies. Available at: https://www.ema.europa.eu
Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015; 348(6230):62–68.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.